Skip to main content

Gayathri R. Devi

Professor in Surgery
Surgery, Surgical Sciences
Box 2606 Med Ctr, Durham, NC
477 Med.Sci.Res.Bldg. (MSRB1), 2606 DUMC, Durham, NC 27710

Overview


Dr. Devi’s research interests include functional genomics, anti-cancer drug discovery and development, mechanisms of cancer cell signaling, tumor immunity and applications thereof for overcoming therapeutic resistance in cancer.

The lab has established prostate, inflammatory breast cancer and ovarian cellular and tumor models.

Current Appointments & Affiliations


Professor in Surgery · 2023 - Present Surgery, Surgical Sciences, Surgery
Professor in Pathology · 2023 - Present Pathology, Clinical Science Departments
Member of the Duke Cancer Institute · 2005 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published November 22, 2023
Urban Environmental Factors Driving Breast Cancer Incidence
Published January 9, 2019
Cancer Cells Steer a Jagged Path
Published March 28, 2017
Study Shows How BPA May Affect Inflammatory Breast Cancer

View All News

Recent Publications


Tumor Microenvironment Modulation by Tumor-Associated Macrophages: Implications for Neoadjuvant Chemotherapy Response in Breast Cancer.

Journal Article Breast Cancer (Dove Med Press) · 2025 BACKGROUND: Tumor-associated macrophages (TAMs) constitute an important part of the tumor microenvironment of breast cancer (BC), and they play an essential role in modulating tumor growth and invasion. However, the role of TAMs in neoadjuvant chemotherapy ... Full text Link to item Cite

Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer.

Journal Article NPJ Breast Cancer · July 29, 2024 Therapeutic resistance presents a significant hurdle in combating inflammatory breast cancer (IBC), adding to the complexity of its management. To investigate these mechanisms, we conducted a comprehensive analysis using transcriptomic and proteomic profil ... Full text Link to item Cite

XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant.

Journal Article Transl Oncol · May 2024 OBJECTIVE: To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic value and new therapeutic targets in in ... Full text Link to item Cite
View All Publications

Recent Grants


Duke University Program in Environmental Health

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2019 - 2029

Medical Scientist Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of General Medical Sciences · 2022 - 2027

Molecular Determinants of Health Disparities in Inflammatory Breast Cancer

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2021 - 2026

View All Grants

Education, Training & Certifications


University of Nebraska, College of Medicine · 1998 Ph.D.